Leo Fu

Co-Founder, CTO

GluBio Therapeutics

Short Biography

Liqiang (Leo) Fu has an extensive work experience in the biotechnology and pharmaceutical industries. Leo is currently working as the Co-Founder and Chief Technology Officer at GluBio Pharmaceutical, Co., Ltd., a position he has held since March 2021. From 2016 to 2021, Leo worked at Johnson & Johnson (Shanghai) Research & Development Center, where he held the position of Principal Scientist and Chemistry Head of Janssen (China) Protein Degradation Drug Discovery. Leo's career began at AbbVie in January 2014, where he worked as a group leader and Senior Scientist of Medicinal Chemistry. He has a track record of inventing or co-inventing several drug candidates that have advanced to clinical trials. Leo has authored or co-authored >20 publications and is an inventor on >20 patents and patent applications. Leo Fu holds a Ph.D. in Medicinal Chemistry from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences and had his postdoctoral training with Prof. Blake R. Peterson at University of Kansas.

Presentation Topic: Development and Exploration of Next-Generation Molecular Glue Protein Degraders

• Serendipitous Discovery of Immunomodulatory Drugs (IMiDs) as Molecular Glues

• Structural Biology and Exploration in Molecular Glue Drug Design

• Advances and Case Studies of Rational Design of Molecular Glues

• Future Perspectives on Molecular Glue Degraders